Divi’s Laboratories is one of the world’s three largest manufacturers of active pharmaceutical ingredients - the chemical core that makes a drug work - but it never sells a finished pill. Founded in 1990 as a research centre near Hyderabad and listed in 2003, the company has grown organically over three decades by staying exclusively on the ingredient side, so it never competes with the pharma companies it supplies. Everything it does runs on a single recurring logic: build deep, backward-integrated manufacturing capacity in advance, master the chemistry in-house, and be ready to produce at scale the moment a customer calls.
Business segments
A single engine with four faces - generic APIs, custom synthesis for innovators, peptides, and nutraceuticals - all running on the same integrated manufacturing backbone and the same chemistry-first approach.
1. Generic APIs: the volume engine that built the house
Divi’s makes 30 off-patent active ingredients at industrial scale and is the world’s largest producer for 10 of them - a position built on cost control, not on chasing every molecule.
- Selective portfolio, massive scale - the company produces a focused range of 30 generic APIs, with volumes spanning from tens to thousands of metric tonnes a year, and holds the number-one global position for a third of them. The portfolio is split between stable, established products like Naproxen and emerging generics like Ticagrelor that are commercialised only after the originator’s patent expires.
- Campaign production frees up capacity - large-volume products such as Naproxen, Dextromethorphan and Gabapentin are made in dedicated campaign runs where plants operate at full stream to build stock, so that multi-purpose equipment is released for other molecules.
- Pricing pressure is a known cycle - the generic business faces persistent price erosion across regulated and unregulated markets, and unlike in custom synthesis, customers do not compensate for raw-material cost increases; the company treats this as a recurring phase that has happened before and stabilises over time.
- Regulatory filings are the entry ticket - the company holds 41 US drug master files, 26 European Certificates of Suitability, and filings with agencies in Canada, Japan and elsewhere, which allow customers to reference Divi’s API in their own drug applications.
2. Custom synthesis: the partnership business with innovators
Divi’s develops and manufactures complex ingredients for 12 of the world’s top 20 pharma companies, earning revenue at project milestones rather than per kilo sold.
- From lab to factory for innovators - the segment works on projects across every clinical phase, from early-stage development through to commercial manufacturing, and the product range is deliberately diversified so no single molecule dominates.
- Paid by milestone, not by volume - revenue arrives when specific stages are reached - qualification, validation, commercial production - which means the business is less exposed to spot-price swings than generics. Raw-material cost increases are also less damaging because customers often compensate for them.
- Contrast media is a specialised pocket - the company makes iodine-based compounds and gadolinium-based MRI contrast agents, sitting inside custom synthesis when the innovator’s process is used, and inside generics when Divi’s own process applies.
- Two large deals locked in recently - in April and May 2025, the company signed long-term supply agreements with two undisclosed global pharma companies for advanced intermediates, together requiring capacity investment of roughly ₹1,300-1,450 crores, funded from internal cash and a customer-paid capacity reservation advance.
3. Peptides: the next growth chemistry
Divi’s is building a position in peptide synthesis - the technology behind GLP-1 drugs - by leveraging decades of experience in the amino acid building blocks that go into them.
- Building blocks are the foundation - the company has long-standing expertise in protected amino acids and is one of the few manufacturers outside China that can supply hundreds of tonnes of the specialised building blocks used in GLP-1 therapies.
- Moving up the chain to fragments - Divi’s is expanding from building blocks into peptide fragment manufacturing (such as octamers and decamers) using both solid-phase and liquid-phase synthesis, and has already validated several fragments with more in the pipeline.
- Engaged with big pharma across phases - the company is working with several large customers on peptide projects at Phase I, II and III stages, all on a custom synthesis basis rather than as generic APIs.
4. Nutraceuticals: the consumer-ingredient side bet
Divi’s makes the carotenoids and vitamins that colour and fortify food, feed and supplements - a business that uses the same integrated manufacturing logic as APIs but sells to a different set of customers.
- Full carotenoid range at scale - the portfolio covers Beta Carotene, Astaxanthin, Lycopene, Canthaxanthin, Lutein and vitamins A, D and E, all produced at a single integrated facility, making the company one of the few global suppliers with the full set.
- Supplies the world’s food and feed giants - the nutraceutical facility is the major supplier of carotenoids to leading food, dietary supplement and feed manufacturers worldwide, and holds food-safety and feed-ingredient certifications including FSSC 22000 and GMP+B2.
- A smaller but growing contributor - the business generated ₹946 crores in the most recent financial year, up from ₹781 crores the year before, and is supported by two overseas marketing subsidiaries in the US and Switzerland.
Manufacturing and technology backbone
Three coastal-adjacent Indian sites, deep backward integration, and a deliberate bet on next-generation chemistry underpin every segment the company operates in.
- Three units, one logic - Unit 1 near Hyderabad (operating since 1995), Unit 2 in Visakhapatnam (since 2003), and the greenfield Unit 3 in Kakinada (first commercial output from January 2025) together hold 16,550 cubic metres of multi-purpose capacity, all approved by US, European and other major regulators.
- Unit 3 unlocks the older plants - the Kakinada site makes starting materials and registered starting materials, so activities are gradually being transferred there from Units 1 and 2, freeing up GMP-compliant space at the older facilities for higher-value finished APIs.
- Backward integration controls cost and quality - the company manufactures most key starting materials in-house, which lets it manage impurity profiles, optimise costs and avoid supply disruption. It also recycles solvents at high rates - roughly 87% of toluene and 93% of nitrobenzene are reused.
- Three technology platforms in commercial use - Divi’s has moved continuous flow chemistry, biocatalysis and green chemistry from R&D into commercial manufacturing, aiming to improve safety, reduce variability and build future-ready capacity.
- ~700 scientists across three R&D centres - the centres in Hyderabad, Choutuppal and Visakhapatnam focus on process development, scale-up and technology transfer, and the company holds multiple process patents.
Group structure and partners
A lean, debt-free structure with two small overseas marketing arms and no joint ventures - the business is run by a family leadership team that splits commercial and technical responsibilities.
- The company has two wholly-owned subsidiaries - Divi’s Laboratories (USA) Inc. in New Jersey and Divi’s Laboratories Europe AG in Basel, Switzerland - both focused on marketing and distributing nutraceutical ingredients in their regions.
- There are no joint ventures or associate companies, and the balance sheet carries zero debt.
- Management is split along functional lines: Nilima Prasad Divi oversees finance, accounting, procurement and supply chain, while Dr. Kiran S. Divi handles production planning, marketing, sales and R&D.